Drugs / L-N-monomethyl Arginine Acetate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02833207 | Apr 2012 → Nov 2021 | obesity disorder | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03446612 Background | Jan → May 2019 | anemia | GlaxoSmithKline | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-N-monomethyl Arginine Acetate | “Drugs: acetylcholine, isoproterenol, bradykinin, adenosine triphosphate, barium chloride, L-N-monomethyl Arginine Acetate, ketorolac.” NCT02833207 ↗ |
| Known as | L-NMMA | “Drug: L-N-monomethyl arginine acetate (L-NMMA)” NCT03446612 ↗ |
| Action | Inhibit | “Antagonists (BaCl2, L-NMMA and ketorolac) will likely reduce EDD responses to agonists” NCT02833207 ↗ |
| Route | Other | “10 minute L-NMMA and ketorolac infusion” NCT02833207 ↗ |